Circulating alpha 1-antitrypsin is synthesized primarily in the liver and secreted into the bloodstream, where it serves as the major protease inhibitor. The PiZ variant of alpha 1-antitrypsin is associated with decreased levels of the protein in sera as a result of its retention within hepatocytes. Homozygosity for the variant allele predisposes individuals to the development of pulmonary emphysema and an increased risk for liver disease. We and others have previously demonstrated that the normal PiM human alpha 1-antitrypsin gene can be properly expressed in the livers of transgenic mice. The PiZ variant of the human alpha 1-antitrypsin gene was introduced into the germline of mice to determine whether the mutant protein would accumulate in mouse hepatocytes and if such accumulation would result in the development of liver damage in an animal model. As expected, the mutant human protein was abundantly synthesized in the livers of the transgenic animals and accumulated within the rough endoplasmic reticulum of hepatocytes as it does in human patients. PiZ mice developed significantly more liver necrosis and inflammation than PiM transgenic mice or control littermates. The degree of liver damage was correlated with the amount of PiZ alpha 1-antitrypsin accumulated in the liver of the different pedigrees of mice. Although 40% of PiZ mice tested were seropositive for mouse hepatitis virus (MHV), the degree of […] 
Introduction a1-Antitrypsin (a,-AT)' is the most abundant serine protease inhibitor in plasma. A major physiological function of this protein appears to be protection of elastic fibers in the lung 1. Abbreviations used in this paper: a -AT, a1-antitrypsin; E, eosin; H, hematoxylin; MHV, mouse hepatitis virus; RER, rough endoplasmic reticulum; SPF, specific pathogen free. from hydrolytic destruction by excessive leukocyte elastase (1) . Among the more than 30 variants of human a1-antitrypsin, the PiZ form is associated with decreased levels of a,-AT in sera (2) . The circulatory deficiency of this protein results from its retention within the rough endoplasmic reticulum (RER) of hepatocytes (3) .
Homozygosity for the PiZ allele predisposes individuals to develop pulmonary emphysema (2) and liver disease, including neonatal cholestasis (3) , cirrhosis (4) , and hepatoma (5) . It has been estimated that -5% of PiZZ infants (6) and 50% of adults with homozygous al-AT deficiency exhibit liver cirrhosis at death (5) . PiMZ heterozygosity may also contribute to the development of chronic liver disease and carcinoma (7-1 1), although the data are controversial (12) .
Considerable data support the hypothesis that alveolar destruction leading to emphysema is caused by an imbalance between leukocyte elastase and as-AT in the lungs, but at present no firm data exist to explain the pathogenesis of liver disease in aI-AT deficiency. This question is of increasing importance at a time when liver transplantation is frequently performed for juvenile cirrhosis (13) and replacement therapy for circulating a,-AT deficiency is available (14) . In this study, we have generated transgenic mice that express the PiZ a1-AT gene to test whether retention of the mutant PiZ protein in hepatocytes is sufficient to cause hepatocellular damage and chronic liver injury. Mice bearing multiple copies of the normal PiM human aI-AT gene (15, 16) and nontransgenic littermates of all transgenic mice have been used as controls for the histopathological evaluation. Methods Production, maintenance, and identification oftransgenic mice. Cloning of the PiZ allele of the human a,-AT gene has previously been reported (15) . Methods for the preparation of the DNA, its microinjection into mouse embryos, and identification of transgenic offspring by Southern blot analysis of mouse tail DNA are identical to those reported for the production oftransgenic mice bearing the normal PiM allele of human a,-AT (15, 16) . At the age of I mo, litters were weaned. Transgenic mice were housed in the same cage as were their sexmatched littermates, and maintained with unlimited access to food (MRH 22/5 Rodent Blox 8840; Premier Lab Diets, Inc., Peoria, IL) (composition available upon request) and fresh water. Original animals were regarded as specific pathogen free (SPF) by suppliers and all animals were maintained under SPF conditions. All experiments were approved by the Baylor institutional review board and followed the guidelines of the National Research Council for the care and use of laboratory animals.
Detection of human a,-antitrypsin in mouse sera. Blood was collected from mice by orbital vein puncture using heparinized capillary tubes. After centrifugation, 2-Ml serum samples were treated with disruption buffer at 90'C for 5 min and proteins were fractionated by SDS-PAGE (17) . Protein bands were identified after Western blotting (18) onto nitrocellulose membranes by species specific antisera as previously described (15) . Quantitation was performed by electroimmunoassay ( 16).
Histopathology. 243 mice aged 6-20 mo from pedigrees bearing the human PiZ and PiM genes and their respective age and sex matched littermates were killed by cervical dislocation and autopsied. Tissues were fixed in Carson Millonig 10% phosphate-buffered formalin, pH 7.4, and embedded in paraffin for light microscopy. Samples were coded to permit unbiased histological analysis by two observers (B. B.
Rogers and M. J. Finegold). Sections stained with hematoxylin (H)-eosin (E), periodic-acid Schiff(PAS), and trichrome were evaluated for each of the following characteristics: (a) presence, quantity, and distribution of hepatocellular globular inclusions; (b) hepatocellular necrosis; (c) cholestasis; (d) lobular inflammation (acute and chronic); (e) portal tract inflammation (acute and chronic); (f) portal fibrosis; (g) architectural disarray; and (h) hyperplastic or regenerating nodules. Each characteristic was scored from 0 to 3+, where 0 was absence of the feature, 1+ was mild, 2+ was moderate, and 3+ was severe.
Sections of selected livers were stained for human a,-AT by standard immunoperoxidase methods (16) . Liver sections from a PiZZ human served as a positive control. Nontransgenic mouse liver and incubation of adjacent sections with nonimmune goat sera provided negative controls.
Electron microscopy. Selected specimens from each group were examined, following standard procedures (16) . Thin sections were stained with uranyl acetate and lead citrate and examined in a Joel 100 C transmission electron microscope. Immunoelectron microscopy was performed as previously described (16) . Goat Equivalent volumes (2.1) of sera from mice were heated in disruption buffer and subjected to SDS-PAGE. After the transfer of the fractionated proteins to nitrocellulose, the filter was subjected to immunoblotting for the detection of human aI-AT using a crude (nonspecies-specific) preparation of goat anti-human aI-AT. (Fig.  3) , and bright red in trichrome stains. Using a peroxidasetagged antibody to human aI-AT, the identity of the accumulated material was confirmed as human a,-AT (Fig. 4) . Purified antisera to mouse al-AT, provided by Dr. Gretchen Darlington of the Pathology Department, Baylor College of Medicine, failed to stain the inclusions. Electron microscopy and immunoelectron microscopy revealed that the accumulated human PiZ a,-AT was localized in the rough endoplasmic reticulum (Figs. 5 and 6 ), just as in the human PiZZ liver. The largest inclusions sometimes exceeded the size ofa normal cell, but most hepatocytes containing them were morphologically intact. However, multiple small foci of necrosis were present, and these areas frequently showed fragmentation of hepatocytes and globules. Associated with such foci were clusters of leukocytes (Fig. 7) . The distribution ofthe globules was panlobular, unlike the human condition, in which periportal hepatocytes are primarily affected. Necrotic foci with inflammation were likewise random in the lobule. However, there were also leukocytic infiltrates in occasional portal tracts and in surrounding terminal hepatic veins not directly associated with al-AT globules.
Fibrosis was infrequent and modest in all groups and never distorted the lobular architecture. Mild degrees (1+) consisted of delicate strands of collagen expanding portal areas or extending in finger-like fashion from portal tracts or terminal hepatic veins into the lobules. Moderate fibrosis (2+) was rare. It was defined as denser patches of collagen occupying the width of a sinusoid. Trichrome stains were used for these estimates.
Cholestasis was observed only once, in a control liver. Bile duct proliferation occurred in small foci of three PiZ transgenic mice. Small nodules of hepatocytes were observed only once in a PiZ mouse and once in a control.
Quantitative analysis of the pathological findings, therefore, was based on inflammation (lobular plus perivenous plus portal), necrosis, and fibrosis. The scores for each alteration in individual animals from each group were tabulated, ranked, and compared. The results are shown in Table I and Fig. 8 . There is a significant increase in inflammation, necrosis, and total pathology score (adding each ofthe categories together) in the PiZ transgenic mice compared with their control littermates and with PiM transgenic mice (P < 0.001). An increase in fibrosis failed to reach statistical significance in PiZ mice versus their controls (P = 0.08). However, a significant increase in fibrosis was observed among PiZ mice versus PiM mice (P = 0.009). Furthermore, PiM mice exhibited no significant increase in pathological findings compared with their controls, even though a,-AT does accumulate in hepatocytes ofPiM mice bearing a high copy number ofthe transgene (16 Therefore, the pathological findings were reanalyzed in rela- o( .#Y of globular inclusions of al-AT in the RER of hepatocytes soon followed (3). These observations were extended to reveal a high prevalence of liver cirrhosis among adult PiZ individuals (5). The only available treatment for the liver disease at this time is orthotopic liver transplantation (13). Of PiZ adults who have been systematically followed, it appears that 50% die at a mean age of 52 yr of severe lung disease. Those subjects have mild or no signs of liver disease. Mortality of the remaining 50% occurs 10 yr later with signs of chronic progressive liver disease at death and milder lung disease (20) . Among PiMZ heterozygotes, lung disease is not significantly increased but chronic progressive liver disease has been found occasionally with progression to cirrhosis and, rarely, hepatoma (1 1). It thus appears that patients with lower rates ofsecretion and low plasma al-AT levels risk rapid development of emphysema, and those with somewhat higher rates of synthesis have better protection of alveolar tissue, but a greater prevalence of liver disease. These epidemiological data have led to the hypothesis that accumulation of a,-AT in the liver is potentially hepatotoxic.
The distinction between the two major forms ofdisease has become important with the availability ofreplacement therapy (14) . If liver disease is caused by a deficiency of the circulating antiprotease rather than by intracellular accumulation, then systemic replacement therapy would be the treatment for both liver and lung disease. However, ifliver disease is caused by an hepatotoxic effect of retained antiprotease, replacement therapy would not be beneficial. (24) . In future experiments, the transgenic PiZ mice will be subjected to chronic low-level hepatotoxicity to determine whether the human pattern of chronic disease can be reproduced.
